Skip to main content

Table 4 Changes in efficacy outcomes before and after 16 weeks of intake

From: Anti-obesity effect of Neoagaro-oligosaccharides with overweight and obese subjects: a 16-week, randomized, double-blind, placebo-controlled clinical trial

Measurements

NAOs group (n = 42)

Placebo group (n = 42)

p-value2)

Baseline

16 week

p-value1)

Baseline

16 week

p-value1)

Abdominal fat CT

TFA (mm2)

33826.214 ± 8327.489

34069.476 ± 8959.364

0.557

33894.190 ± 6839.269

34558.452 ± 7820.549

0.105

0.465

VFA (mm2)

7860.400 ± 3268.930

7466.425 ± 3233.311

0.060

8003.375 ± 2823.643

8201.800 ± 2996.630

0.180

0.021*

SFA (mm2)

25325.738 ± 6121.032

25869.095 ± 6777.136

0.114

24966.317 ± 5861.417

25384.927 ± 6208.211

0.177

0.785

VSR

0.316 ± 0.123

0.294 ± 0.121

0.011*

0.340 ± 0.153

0.341 ± 0.152

0.826

0.023*

Anthropometric parameters

Weight (kg)

67.436 ± 6.917

67.412 ± 7.272

0.939

68.690 ± 7.578

69.917 ± 8.267

0.0001***

0.004**

BMI (kg/m2)

26.324 ± 2.139

26.321 ± 2.383

0.984

25.963 ± 1.874

26.407 ± 2.124

0.0001***

0.007**

WC (cm)

86.881 ± 6.663

86.895 ± 7.244

0.975

87.526 ± 7.074

88.388 ± 7.462

0.054

0.177

HC (cm)

99.652 ± 3.714

99.712 ± 3.527

0.876

100.712 ± 4.703

101.164 ± 5.322

0.135

0.417

WHR

0.876 ± 0.054

0.875 ± 0.054

0.957

0.880 ± 0.051

0.885 ± 0.047

0.218

0.426

DEXA

BFM (g)

22478.357 ± 4305.502

23066.833 ± 4784.854

0.032*

22449.200 ± 3663.866

23421.650 ± 3967.897

0.001**

0.324

PBF (%)

33.969 ± 4.316

34.567 ± 4.747

0.038*

33.921 ± 3.346

34.838 ± 3.864

0.002**

0.414

LBM (g)

43438.810 ± 4606.042

43294.143 ± 4496.329

0.393

44408.429 ± 4276.123

44644.548 ± 4460.618

0.114

0.091

Lipid profiles

Total cholesterol (mg/dL)

204.381 ± 32.628

207.048 ± 27.304

0.421

199.024 ± 35.771

194.333 ± 30.920

0.177

0.124

LDL-C (mg/dL)

125.857 ± 30.608

133.310 ± 30.205

0.013*

118.190 ± 30.560

116.619 ± 24.765

0.567

0.025*

HDL-C (mg/dL)

58.195 ± 10.378

60.098 ± 10.712

0.093

57.439 ± 10.943

56.415 ± 11.709

0.430

0.088

Triglyceride (mg/dL)

103.714 ± 54.035

100.571 ± 44.591

0.637

104.077 ± 47.473

114.846 ± 63.831

0.218

0.200

  1. NAOs, Neoagaro-oligosaccharides; CT, computed tomography; TFA, total abdominal fat area; VFA, visceral fat area; SFA, subcutaneous fat area; VSR, visceral-subcutaneous fat area ratio; BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-hip ratio; DEXA, dual-energy X-ray absorptiometry; BFM, Body fat mass; PBF, percent body fat; LBM, lean body mass; LDL-C, low-density lipoprotein- cholesterol; HDL-C, high-density lipoprotein- cholesterol
  2. Values are presented as the mean ± SD
  3. 1) Analyzed by paired t-test between baseline and 16 weeks within each group (Weeks 0 vs. 16)
  4. 2) Analyzed by independent t-test for change value between the groups (NAOs vs. Placebo)
  5. *p < 0.05, **p < 0.01, ***p < 0.001
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us